Association study of protease activated receptor 1 gene polymorphisms and adverse pregnancy outcomes: Results of a pilot study in Israel

American Journal of Medical Genetics, Part A

Volumn 143, Issue 21, 2007, Pages 2557-2563

  Grisaru Granovsky, Sorina ^a,b   Tevet, Aharon ^a   Bar Shavit, Rachel ^b   Salah, Zaidoun ^b   Elstein, Deborah ^a   Samueloff, Arnon ^a   Altarescu, Gheona ^a  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

F2R gene polymorphism; Placentation; Preterm delivery; Protease activated receptors; Thrombin receptor

Indexed keywords

CELL ADHESION MOLECULE; PROTEINASE ACTIVATED RECEPTOR 1; THROMBIN RECEPTOR;

ARTICLE; BLOOD CLOTTING; CASE CONTROL STUDY; CONTROLLED STUDY; GENE FREQUENCY; GENE INSERTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEMOSTASIS; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; ISRAEL; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PREECLAMPSIA; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PREMATURE LABOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; REPRODUCTION; SMALL FOR DATE INFANT;

ADULT; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENOTYPE; GESTATIONAL AGE; HAPLOTYPES; HUMANS; INFANT, NEWBORN; INFANT, SMALL FOR GESTATIONAL AGE; ISRAEL; PILOT PROJECTS; POLYMORPHISM, GENETIC; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PREMATURE BIRTH; PROSPECTIVE STUDIES; RECEPTOR, PAR-1;

EID: 35848966800     PISSN: 15524825     EISSN: 15524833     Source Type: Journal    
DOI: 10.1002/ajmg.a.31985     Document Type: Article

References (34)

1. Aagaard-Tillery KM, Stoddard GJ, Holmgren C, Lacoursiere DY, Fraser A, Mineau GP, Varner MW. 2006. Preeclampsia and subsequent risk of cancer in Utah. Am J Obstet Gynecol 195:691-699.
2. Arnaud E, Nicaud V, Poirier O, Rendu F, Alhenc-Gelas M, Fiessinger JN, Emmerich J, Aiach M. 2000. Protective effect of a thrombin receptor (protease-activated receptor 1) gene polymorphism toward venous thromboembolism. Arterioscler Thromb Vasc Biol 20:585-592.
3. Boire A, Covic L, Agarwal A, Jacques S, Sherifi S, Kuliopulos A. 2005. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120:303-313.
4. Booden MA, Eckert LB, Der CJ, Trejo J. 2004. Persistent signaling by dysregulated thrombin receptor trafficking promotes breast carcinoma cell invasion. Mol Cell Biol 24:1990-1999.
5. Camerer E, Cornelissen I, Kataoka H, Duong DN, Zheng YW, Coughlin SR. 2006. Roles of protease-activated receptors in a mouse model of endotoxemia. Blood 107:3912-3921.
6. Clausson B, Lichtenstein P, Cnattingius S. 2000. Genetic influence on birthweight and gestational length determined by studies in offspring of twins. BJOG 107:375-381.
7. Coughlin SR. 1999. How the protease thrombin talks to cells. Proc Natl Acad Sci USA 96:11023-11027.
8. Crider KS, Whitehead N, Buus RM. 2005. Genetic variation associated with preterm birth: A HuGE review. Genet Med 7:593-604.
9. den Dunnen JT, Antonarakis SE. 2000. Mutation nomenclature extensions and suggestions to describe complex mutations: A discussion. Hum Mutat 15:7-12.
10. Dollberg S, Haklai Z, Mimouni FB, Gorfein I, Gordon ES. 2005. Birth weight standards in the live-born population in Israel. Isr Med Assoc J 7:311-314.
11. Dupont A, Fontana P, Bachelot-Loza C, Reny JL, Bieche I, Desvard F, Aiach M, Gaussem P. 2003. An intronic polymorphism in the PAR-1 gene is associated with platelet receptor density and the response to SFLLRN. Blood 101:1833-1840.
12. Even-Ram SC, Grisaru-Granovsky S, Pruss D, Maoz M, Salah Z, Yong-Jun Y, Bar-Shavit R. 2003. The pattern of expression of protease-activated receptors (PARs) during early trophoblast development. J Pathol 200:47-52.
13. Grisaru-Granovsky S, Salah Z, Maoz M, Pruss D, Beller U, BarShavit R. 2005. Differential expression of protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples. Int J Cancer 113:372-378.
14. Hattersley AT, McCarthey MI. 2005. What makes a good genetic association study? The Lancet 366:1315-1323.
15. Johansson S, Iliadou A, Bergvall N, Tuvemo T, Norman M, Cnattingius S. 2005. Risk of high blood pressure among young men increases with the degree of immaturity at birth. Circulation 112:3430-3436.
16. Menon R, Velez DR, Simhan H, Ryckman K, Jiang L, Thorsen P, Vogel I, Jacobsson B, Merialdi M, Williams SM, Fortunato SJ. 2006. Mulitlocus interactions at maternal tumor necrosis factor-α, tumor necrosis factor receptors, interleukin-6 and interleukin-6 receptor genes predict spontaneous preterm labor in European-American Women. Am J ObGyn 194:1616-1624.
17. Montgomery AA, Ben-Shlomo Y, McCarthy A, Davies D, Elwood P, Smith GD. 2000. Birth size and arterial compliance in young adults. Lancet 355:2136-2137.
18. National Center for Health Statistics. 2002. Births: Final data for 2002. Available at http://www.cdc.gov/nchs/Default.htm.
19. O'Brien PJ, Koi H, Parry S, Brass LF, Strauss JF III, Wang LP, Tomaszewski JE, Christenson LK. 2003. Thrombin receptors and protease-activated receptor-2 in human placentation: Receptor activation mediates extravillous trophoblast invasion in vitro. Am J Pathol 163:1245-1254.
20. O'Loughlin AJ, O'Sullivan CJ, Ravikumar N, Friel AM, Elliott JT, Morrison JJ. 2005. Effects of thrombin, PAR-1 activating peptide and a PAR-1 antagonist on umbilical artery resistance in vitro. Reprod Biol Endocrinol 3:8.
21. Pell JP, Smith GC, Walsh D. 2004. Pregnancy complications and subsequent maternal cerebrovascular events: A retrospective cohort study of 119,668 births. Am J Epidemiol 159:336-342.
22. Ray JG, Vermeulen M, Schull M, Redelmeir DA. 2005. Cardiovascular health after maternal placental syndromes (CHAMPS): Population based retrospective cohort study. Lancet 366: 1797-1803.
23. Reiter R, Derhaschnig U, Spiel A, Keen P, Cardona F, Mayr F, Jilma B. 2003. Regulation of protease-activated receptor 1 (PAR1) on platelets and responsiveness to thrombin receptor activating peptide (TRAP) during systemic inflammation in humans. Thromb Haemost 90:898-903.
24. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. 2000. Am J Obstet Gynecol 183:S1-S22.
25. Rosen T, Schatz F, Kuczynski E, Lam H, Koo AB, Lockwood CJ. 2002. Thrombin-enhanced matrix metalloproteinase-1 expression: A mechanism linking placental abruption with premature rupture of the membranes. J Matern Fetal Neonatal Med 11:11-17.
26. Ruf W, Mueller BM. 2006. Thrombin generation and the pathogenesis of cancer. Semin Thromb Hemost 32:61-68.
27. Smith GC, Pell JP, Walsh D. 2001. Pregnancy complications and maternal risk of ischaemic heart disease: A retrospective cohort study of 129,290 births. Lancet 357:2002-2006.
28. Sood R, Kalloway S, Mast AE, Hillard CJ, Weiler H. 2006. Fetomaternal cross talk in the placental vascular bed: Control of coagulation by trophoblast cells. Blood 107:3173-3180.
29. Stephens M, Smith NJ, Donnelly P. 2001. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68:978-989.
30. Vadillo-Ortega F, Estrada-Gutierrez G. 2005. Role of matrix metalloproteinases in preterm labour. BJOG 112:19-22.
31. Vegh GL, Selcuk Tuncer Z, Fulop V, Genest DR, Mok SC, Berkowitz RS. 1999. Matrix metalloproteinases and their inhibitors in gestational trophoblastic diseases and normal placenta. Gynecol Oncol 75:248-253.
32. Ward K, Argyle VA, Nelson L. 2005. The heritability of preterm delivery. Obstet Gynecol 106:1235-1239.
33. Winkvist A, Morgen I, Hogberg U. 1998. Familial patterns in birth characteristics: Impact on individual and population risks. Int J Epidemiol 27:248-254.
34. Xiong X, Fraser WD, Demianczuk NN. 2002. History of abortion, preterm, term birth and risk of preeclampsia: A population based study. Am J Obstet Gynecol 187:1013-1018.